Compounded vs Brand GLP-1: What Actually Changed by 2026

What changed, in order

Prices and regulatory status checked 2 September 2026; both change often.

Date	What happened
19 Dec 2024	FDA determines the tirzepatide injection shortage resolved
19 Feb 2025	Cut-off for 503A state-licensed pharmacies compounding tirzepatide
21 Feb 2025	FDA announces the semaglutide shortage resolved
19 Mar 2025	Cut-off for 503B outsourcing facilities compounding tirzepatide
22 Apr 2025	Enforcement discretion ends for 503A pharmacies compounding semaglutide
22 May 2025	Enforcement discretion ends for 503B facilities compounding semaglutide
Sep 2025	FDA begins a broad enforcement push on compounded GLP-1 marketing
3 Mar 2026	FDA announces warning letters to 30 telehealth companies
Jun 2026	A further 25 warning letters over compounded GLP-1 promotional claims
12 Aug 2026	Lilly files six lawsuits against sellers of retatrutide copies

The shortage ended — and that mattered more than anything else

Mass compounding of GLP-1 copies was built on a shortage exception. When a drug is on the FDA shortage list, compounders have latitude to prepare copies of it that would otherwise be off limits. That latitude closed in stages: tirzepatide's shortage was determined resolved on 19 December 2024, semaglutide's on 21 February 2025, and the FDA set staged compounding cut-offs — 19 February 2025 (503A) and 19 March 2025 (503B) for tirzepatide, 22 April 2025 (503A) and 22 May 2025 (503B) for semaglutide.

The distinction between those two facility types is worth holding onto, because it decides what a pharmacy may lawfully do:

• 503A — a state-licensed pharmacy compounding for an individual patient against an individual prescription.
• 503B — an outsourcing facility that registers with the FDA, is subject to CGMP requirements, and may compound in larger batches without patient-specific prescriptions.

Compounding did not stop after those dates; the shortage-based justification for producing copies of the approved drugs did. What remains is a narrower, fact-specific set of circumstances, and a website cannot tell you whether a given prescription falls inside it.

What the FDA actually says

Four statements from the agency's own GLP-1 page carry most of the weight:

1. "Compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed."
2. Salt forms: "These salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs." The agency has said it lacks safety information for them.
3. Dosing errors: "FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products."
4. Doses "beyond what is in the FDA-approved drug label" — higher single doses, increased frequency, or accelerated titration — are singled out as a concern.

Point 4 is the one that sits awkwardly with the industry's favourite selling phrase. "Personalised to your dose" is marketing language, and the availability of an off-label strength is not by itself evidence that it is appropriate or lawfully compounded.

Two waves of warning letters

On 3 March 2026 the FDA announced 30 warning letters to telehealth companies marketing compounded GLP-1 products. Its stated concerns were "making claims implying sameness with FDA-approved products" and "obscuring product sourcing by advertising drug products branded with the telehealth firm's name or trademark without qualification" — the agency's view being that these firms implied they were the compounders when they were not. The announcement described this as the second batch since an enforcement push began in September 2025, and said the agency had sent more cautionary letters to pharmaceutical and telehealth firms in six months than in the prior decade.

A further 25 warning letters followed in June 2026, reported as targeting false or misleading promotional claims about compounded semaglutide and tirzepatide, including equivalence claims and the use of "FDA-approved" sourcing language in weight-loss marketing. We have not verified an FDA press announcement for the June wave from a primary FDA URL; it is reported consistently across trade and legal press.

The litigation, stated accurately

On 12 August 2026 Eli Lilly filed six lawsuits — against Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide. Those suits concerned retatrutide, an experimental compound that has no FDA approval at all, rather than compounded tirzepatide. That distinction is worth making precisely, because the two get merged in coverage: Lilly has pursued separate actions and cease-and-desist activity against tirzepatide compounders and telehealth sellers over a longer period, and the FDA has stated that consumer sales of retatrutide and other unapproved GLP-1 versions are illegal and cannot lawfully be compounded.

Meanwhile, the price gap widened

None of the above stopped the advertised price of compounded GLP-1s from falling. RonanRx's own page, fetched 2 September 2026, advertises compounded tirzepatide from $78 per 30 days of medication plus a $39 monthly physician fee, renewing "starting at $117/month" — against a Lilly self-pay ladder that runs $299 to $699 a month for Zepbound.

The vendor's own page states the caveat the FDA states: "Compounded medicines are prepared by a licensed pharmacy and are not FDA-approved, and they are not reviewed by the FDA for safety or effectiveness." We quote one vendor because its figures were published and checkable. We do not rank vendors, link to checkout, or take referral fees.

So the honest summary of 2026 is a widening gap between a tightening regulatory position and a falling advertised price. Anyone choosing on price alone should at least know they are choosing across a category boundary, not along a discount curve. If you are already prescribed a compounded product, what a patient can actually verify is the practical follow-on.

Related reading

• GLP-1 cost guide 2026
• Is compounded semaglutide safe? What to check
• Tirzepatide cost in 2026
• Semaglutide cost in 2026